Literature DB >> 16871541

Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure.

Volker Schmitz1, Frank Dombrowski, Jesús Prieto, Cheng Qian, Linda Diehl, Percy Knolle, Tilman Sauerbruch, Wolfgang H Caselmann, Ulrich Spengler, Ludger Leifeld.   

Abstract

Previously, we demonstrated that intrahepatic upregulation of the immunoactivating molecules CD40 and CD40 ligand (CD40L) are early mechanisms for liver cell damage in human and murine fulminant hepatic failure (FHF). In the present study, we investigated the functional effects of intrahepatic overexpression of CD40L by adenoviral-mediated gene transfer (AdCD40L) in mice. AdCD40L injection induced severe liver cell damage, which was associated with increased alanine aminotransferase (ALT) levels peaking at day 5 after vector administration (AdCD40L, 1,707 +/- 279 U/L; AdLacZ, 213 +/- 25 U/L) and with lethality in half of the mice. Except for mild splenomegaly, no organs other than the liver were involved in inflammatory reactions. CD40-CD40L interaction was mandatory for liver damage, because CD40(-/-) mice were completely protected. Furthermore, CD40L-induced FHF depended on competent lymphocytes, because inflammatory reactions were strongly decreased in SCID and Rag1(-/-) mice. In contrast, neither natural killer T (NKT) cells nor Kupffer cells relevantly influenced histology as shown in NKT cell-deficient CD1d(-/-) mice and by gadolinium depletion of Kupffer cells. Furthermore, immunosuppression by dexamethasone and cyclosporin A was not sufficient to block CD40L damage. In conclusion, we present a model of FHF with strong similarities to human FHF with respect to time course and histological changes. This model suggests involvement of the CD40-CD40L system in FHF and might have important implications for future pathophysiological studies of this condition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16871541     DOI: 10.1002/hep.21274

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Hybrid bioartificial liver support in cynomolgus monkeys with D-galactosamine-induced acute liver failure.

Authors:  Zhi Zhang; Yi-Chao Zhao; Yuan Cheng; Guo-Deng Jian; Ming-Xin Pan; Yi Gao
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

2.  Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

Authors:  Cory L Ahonen; Anna Wasiuk; Shinichiro Fuse; Mary Jo Turk; Marc S Ernstoff; Arief A Suriawinata; James D Gorham; Ross M Kedl; Edward J Usherwood; Randolph J Noelle
Journal:  Blood       Date:  2008-01-17       Impact factor: 22.113

Review 3.  An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure.

Authors:  María-Jesús Tuñón; Marcelino Alvarez; Jesús-M Culebras; Javier González-Gallego
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

4.  Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles.

Authors:  Vikas K Verma; Haiyang Li; Ruisi Wang; Petra Hirsova; Malek Mushref; Yaming Liu; Sheng Cao; Patricia C Contreras; Harmeet Malhi; Patrick S Kamath; Gregory J Gores; Vijay H Shah
Journal:  J Hepatol       Date:  2015-11-26       Impact factor: 25.083

5.  Hepatocyte growth factor in dampening liver immune-mediated pathology in acute viral hepatitis without compromising antiviral activity.

Authors:  Renan Aguilar-Valenzuela; Eric D Carlsen; Yuejin Liang; Lynn Soong; Jiaren Sun
Journal:  J Gastroenterol Hepatol       Date:  2014-04       Impact factor: 4.029

6.  Inflammatory cascades driven by tumor necrosis factor-alpha play a major role in the progression of acute liver failure and its neurological complications.

Authors:  Anne Chastre; Mireille Bélanger; Elizabeth Beauchesne; Bich N Nguyen; Paul Desjardins; Roger F Butterworth
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

7.  Serum soluble CD40 is associated with liver injury in patients with chronic hepatitis B.

Authors:  Hong-Hui Shen; Bing-Ke Bai; Ya-Qing Wang; Guang-DE Zhou; Jun Hou; Yan Hu; Jing-Min Zhao; Bao-Sen Li; Hai-Li Huang; Pan-Yong Mao
Journal:  Exp Ther Med       Date:  2015-01-14       Impact factor: 2.447

8.  Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver.

Authors:  Julia Volckmar; Marcus Gereke; Thomas Ebensen; Peggy Riese; Lars Philipsen; Stefan Lienenklaus; Dirk Wohlleber; Robert Klopfleisch; Sabine Stegemann-Koniszewski; Andreas J Müller; Achim D Gruber; Percy Knolle; Carlos A Guzman; Dunja Bruder
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

9.  Perforin inhibition protects from lethal endothelial damage during fulminant viral hepatitis.

Authors:  M Welz; S Eickhoff; Z Abdullah; J Trebicka; K H Gartlan; J A Spicer; A J Demetris; H Akhlaghi; M Anton; K Manske; D Zehn; B Nieswandt; C Kurts; J A Trapani; P Knolle; D Wohlleber; W Kastenmüller
Journal:  Nat Commun       Date:  2018-11-15       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.